Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Jud, P; Sourij, H.
Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review.
Diabetes Res Clin Pract. 2019; 148:54-63
Doi: 10.1016/j.diabres.2018.11.016
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Jud Philipp
- Co-Autor*innen der Med Uni Graz
- Sourij Harald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Diabetes mellitus (DM) defines metabolic disorders, characterised by elevated levels of blood glucose. Chronic hyperglycaemic state promotes consequently the formation of advanced glycation end products (AGEs) and the expression of their receptor (RAGE) which aggravate many diabetic complications. Due to the relevant role of AGEs and RAGE, several therapeutic approaches with an anti-AGE or RAGE-antagonizing effect are investigated. These therapeutic options include AGE cross-link breakers, AGE inhibitors, RAGE antagonists, drugs clinically approved for various indications like antidiabetic, antihypertensive drugs or statins, as well as dietary and phytotherapeutic approaches. The aim of this review is to give an overview of these therapeutic approaches, their outcomes in clinical studies and their role in the management of diabetes and its complications. Copyright © 2018 Elsevier B.V. All rights reserved.
- Find related publications in this database (Keywords)
- Diabetes mellitus
- Advanced glycation end products
- AGE cross-link breaker
- AGE inhibitors
- RAGE antagonists